Matthew J. Budoff MD
University of California, Los Angeles
H-index: 159
North America-United States
Description
Matthew J. Budoff MD, With an exceptional h-index of 159 and a recent h-index of 111 (since 2020), a distinguished researcher at University of California, Los Angeles, specializes in the field of Cardiology, Atherosclerosis, Cardiac Imaging.
His recent articles reflect a diverse array of research interests and contributions to the field:
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial
Closing the Last Mile Gap in Access to Multimodality Imaging in Rural Settings: Design of the Imaging Core of the Risk Underlying Rural Areas Longitudinal Study
Social disadvantage, coronary artery calcium, and their interplay in the prediction of atherosclerotic cardiovascular disease events
The Impact of Semaglutide on Liver Fat Assessed by Serial Cardiac CT scans in Patients with Type 2 Diabetes: Results from STOP Trial
Coronary artery calcium score predicts major adverse cardiovascular events in stable chest pain
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Prediction of the development of new coronary atherosclerotic plaques with radiomics
Nontraditional Risk Markers for Incident Coronary Artery Calcium Among Persons≥ 65 Years of Age
Professor Information
University | University of California, Los Angeles |
---|---|
Position | David Geffen School of Medicine at |
Citations(all) | 189834 |
Citations(since 2020) | 81175 |
Cited By | 130671 |
hIndex(all) | 159 |
hIndex(since 2020) | 111 |
i10Index(all) | 1073 |
i10Index(since 2020) | 824 |
University Profile Page | University of California, Los Angeles |
Research & Interests List
Cardiology
Atherosclerosis
Cardiac Imaging
Top articles of Matthew J. Budoff MD
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial
ImportanceCardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years.ObjectiveTo investigate the effects of pitavastatin on noncalcified coronary artery plaque by coronary computed tomography angiography (CTA) and on inflammatory biomarkers as potential mechanisms for MACE prevention.Design, Setting, and ParticipantsThis double-blind, placebo-controlled randomized clinical trial enrolled participants from April 2015 to February 2018 at 31 US clinical research sites.PWH without known CVD who were taking antiretroviral therapy and had low to moderate 10-year CVD risk were included. Data were analyzed from April to November 2023.InterventionOral …
Authors
Michael T Lu,Heather Ribaudo,Borek Foldyna,Markella V Zanni,Thomas Mayrhofer,Julia Karady,Jana Taron,Kathleen V Fitch,Sara McCallum,Tricia H Burdo,Kayla Paradis,Sandeep S Hedgire,Nandini M Meyersohn,Christopher DeFilippi,Carlos D Malvestutto,Audra Sturniolo,Marissa Diggs,Sue Siminski,Gerald S Bloomfield,Beverly Alston-Smith,Patrice Desvigne-Nickens,Edgar T Overton,Judith S Currier,Judith A Aberg,Carl J Fichtenbaum,Udo Hoffmann,Pamela S Douglas,Steven K Grinspoon,Eric S Daar,Babafemi Taiwo,Susan L Koletar,Kara W Chew,Susan J Little,Sonya L Heath,Jeffrey M Jacobson,Rajesh Gandhi,Gregory Robbins,Rachel M Presti,Marshall Glesby,Annie Luetkemeyer,Pablo Tebas,Sharon A Riddler,Michael P Dube,Jorge L Santana-Bagur,E Sha Beverly,Jennifer Manne,Roberto Arduino,Charles W Flexner,David W Haas,David A Wohl,Magdalena E Sobieszczyk,Karen T Tashima,Sonal S Munsiff,Rachel Bender Ignacio,Kristen Marks,Cornelius Van Dam,Shobha Swaminathan,Thomas B Campbell,Patricia Bandettini,Gerald Bloomfield,Judith Currier,Peter Kim,Heather J Ribaudo,Yves Rosenberg,James Troendle,Mark Byroads,Elaine Gershman,Folake Lawal,Jorge Leon-Cruz,Rochelle Louis,Cheryl Lowe,Eva Moy,Triin Umbleja,Namrata Upadhyay,Stephen Wiviott,Kenneth Wood,Oladapo Anthony,Radhika Barve,Fred Bone,Selina Bannoo,Annie Duffy,Carl Fletcher,Madison Green,Nory Klop-Packel,Emilia Norton,Jennifer Nowak,Maria Sanchez Grande,Eloise Walker,David Vlieg,Tricia Burdo,Laura Moran,Jhoanna Roa,Heather Sprenger,Bola Adedeji,Oladapo Alli,Blanca Castillo,Joan Dragavon,Keisha Easley,Julian Falutz,Ewelinka Grzejka,Erin Hoffman,Yuji Liao,Sara Looby,Dana Nohynek,Mary Pate,James Rooney,Akbar Shahkolahi,Craig Sponseller,Kenneth Williams,Markella Zanni,Kate Borloglou,Meredith Clement,Allison Eckard,Rebecca LeBlanc,Carlos Malvestutto,Edgar T Overton,Karl Shaw,Virginia Triant,Amy Kantor,Jennifer M Manne-Goehler,Kate Starr,Ronald Barnett,Jane Baum,Cindy Coates,Sandra W Cordoso,Christie Lyn Costanza,Sylvia Davila,Dushyantha Jayaweera,Teri Greenfield,Howard Gutzman,Regina Harden,Sarah Henn,MJ Humphries,Mamta Jain,David Klein,Sharon Kohrs,Javier Lama,Jessica Landis,Jaclyn Leone,Rita Lira,Maria Martinez,Richard Novak,Karen Reese,Breno Santos,Jenese Tucker,Aimee Wilkin,Tomeka Wilson,Barbara Bastow,Francoise Giguel,Nada Saleh
Journal
JAMA cardiology
Published Date
2024/2/21
Closing the Last Mile Gap in Access to Multimodality Imaging in Rural Settings: Design of the Imaging Core of the Risk Underlying Rural Areas Longitudinal Study
Achieving optimal cardiovascular health in rural populations can be challenging for several reasons including decreased access to care with limited availability of imaging modalities, specialist physicians, and other important health care team members. Therefore, innovative solutions are needed to optimize health care and address cardiovascular health disparities in rural areas. Mobile examination units can bring imaging technology to underserved or remote communities with limited access to health care services. Mobile examination units can be equipped with a wide array of assessment tools and multiple imaging modalities such as computed tomography scanning and echocardiography. The detailed structural assessment of cardiovascular and lung pathology, as well as the detection of extracardiac pathology afforded by computed tomography imaging combined with the functional and hemodynamic …
Authors
Hooman Fazlalizadeh,Muhammad Shahzeb Khan,Ervin R Fox,Pamela S Douglas,David Adams,Michael J Blaha,Melissa A Daubert,Gary Dunn,Edwin van den Heuvel,Michelle D Kelsey,Randolph P Martin,James D Thomas,Yngvil Thomas,Suzanne E Judd,Ramachandran S Vasan,Matthew J Budoff,Gerald S Bloomfield
Journal
Circulation: Cardiovascular Imaging
Published Date
2024/2
Social disadvantage, coronary artery calcium, and their interplay in the prediction of atherosclerotic cardiovascular disease events
Background and aimsSocial determinants of health (SDOH) are key for the identification of populations at increased risk of atherosclerotic cardiovascular disease (ASCVD). However, whether at the individual level SDOH improve current ASCVD risk prediction paradigms beyond traditional risk factors and the coronary artery calcium (CAC) score, is unknown. We evaluated the interplay between CAC and SDOH in ASCVD risk prediction.MethodsMESA is a prospective study of US adults free of clinical ASCVD at baseline. We used an SDOH index inclusive of 14 determinants from 5 domains. The index ranged 0–1 and was divided into quartiles, with higher ones representing worse SDOH. Cox regression was used to evaluate the adjusted associations between CAC, SDOH, their interplay, and ASCVD events. The C-statistic was computed to assess improvement in risk discrimination for prediction of ASCVD events …
Authors
Isaac Acquah,Miguel Cainzos-Achirica,Mohamad B Taha,Shubham Lahan,Michael J Blaha,Sadeer G Al-Kindi,Safi U Khan,Garima Sharma,Matthew J Budoff,Khurram Nasir
Journal
Atherosclerosis
Published Date
2023/10/25
The Impact of Semaglutide on Liver Fat Assessed by Serial Cardiac CT scans in Patients with Type 2 Diabetes: Results from STOP Trial
IntroductionThere is increasing prevalence of hepatic steatosis. Hepatic steatosis is increasingly recognized as the independent risk factor for cardiovascular mortality. However, there are limited options for the treatment of fatty liver. In this study we evaluated the effect of semaglutide on liver fat as measured by non-contrast cardiac CT scans.MethodsSTOP is a randomized controlled trial that evaluated semaglutide treatment effect on coronary atherosclerosis progression (STOP) in type 2 diabetes. We utilized unenhanced cardiac CT scans to quantify liver fat based on CT Hounsfield attenuation method. A total of 114 subjects qualified for this study of the 140 subjects randomized, 59 in semaglutide group and 55 in the placebo group and were followed for 12 months. Multivariate regression models were used to evaluate the change in liver fat content overtime.Results114 subjects were included in the study, 61 …
Authors
Venkat Sanjay Manubolu,April Kinninger,Jairo Aldana-Bitar,Keishi Ichikawa,Hooman Fazlalizadeh,Leili Pourafkari,Khadije Ahmad,Shriraj Susarla,Czarina Mangaoang,Ahmed K Ghanem,Denise Alison Javier,Sajad Hamal,Sion K Roy,Matthew J Budoff
Journal
American Heart Journal
Published Date
2024/1/1
Coronary artery calcium score predicts major adverse cardiovascular events in stable chest pain
Background Coronary artery calcium (CAC) has prognostic value for major adverse cardiovascular events (MACE) in asymptomatic individuals, whereas its role in symptomatic patients is less clear. Purpose To assess the prognostic value of CAC scoring for MACE in participants with stable chest pain initially referred for invasive coronary angiography (ICA). Materials and Methods This prespecified subgroup analysis from the Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) trial, conducted between October 2015 and April 2019 across 26 centers in 16 countries, focused on adult …
Authors
Federico Biavati,Luca Saba,Melinda Boussoussou,Klaus F Kofoed,Theodora Benedek,Patrick Donnelly,José Rodríguez-Palomares,Andrejs Erglis,Cyril Štěchovský,Gintarė Šakalytė,Nada Čemerlić Ađić,Matthias Gutberlet,Jonathan D Dodd,Ignacio Diez,Gershan Davis,Elke Zimmermann,Cezary Kępka,Radosav Vidakovic,Marco Francone,Małgorzata Ilnicka-Suckiel,Fabian Plank,Juhani Knuuti,Rita Faria,Stephen Schröder,Colin Berry,Balazs Ruzsics,Nina Rieckmann,Christine Kubiak,Kristian Schultz Hansen,Jacqueline Müller-Nordhorn,Pál Maurovich-Horvat,Per E Sigvardsen,Imre Benedek,Clare Orr,Filipa Xavier Valente,Ligita Zvaigzne,Vojtěch Suchánek,Antanas Jankauskas,Filip Ađić,Michael Woinke,Diarmaid Cadogan,Iñigo Lecumberri,Erica Thwaite,Mariusz Kruk,Aleksandar N Neskovic,Massimo Mancone,Donata Kuśmierz,Gudrun Feuchtner,Mikko Pietilä,Vasco Gama Ribeiro,Tanja Drosch,Christian Delles,Riccardo Cau,Michael Fisher,Bela Merkely,Charlotte Kragelund,Rosca Aurelian,Stephanie Kelly,Bruno García del Blanco,Ainhoa Rubio,Bálint Szilveszter,Jens D Hove,Ioana Rodean,Susan Regan,Hug Cuéllar Calabria,István Ferenc Édes,Linnea Larsen,Roxana Hodas,Adriane E Napp,Robert Haase,Sarah Feger,Mahmoud Mohamed,Lina M Serna-Higuita,Konrad Neumann,Henryk Dreger,Matthias Rief,Viktoria Wieske,Matthew J Budoff,Melanie Estrella,Peter Martus,Maria Bosserdt,Marc Dewey,DISCHARGE Trial Group
Journal
Radiology
Published Date
2024/3/5
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
BackgroundThe EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.MethodsEMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease …
Authors
Parminder K Judge,Natalie Staplin,Kaitlin J Mayne,Christoph Wanner,Jennifer B Green,Sibylle J Hauske,Jonathan R Emberson,David Preiss,Sarah YA Ng,Alistair J Roddick,Emily Sammons,Doreen Zhu,Michael Hill,Will Stevens,Karl Wallendszus,Susanne Brenner,AK Cheung,ZH Liu,J Li,LS Hooi,WJ Liu,T Kadowaki,M Nangaku,A Levin,D Cherney,AP Maggioni,R Pontremoli,R Deo,S Goto,X Rossello,KR Tuttle,D Steubl,D Massey,MJ Landray,C Baigent,R Haynes,WG Herrington,S Abat,R Abd Rahman,R Abdul Cader,MI Abdul Hafidz,MZ Abdul Wahab,NK Abdullah,T Abdul-Samad,M Abe,N Abraham,S Acheampong,P Achiri,JA Acosta,A Adeleke,V Adell,R Adewuyi-Dalton,N Adnan,A Africano,M Agharazii,F Aguilar,A Aguilera,M Ahmad,MK Ahmad,NA Ahmad,NH Ahmad,NI Ahmad,N Ahmad Miswan,H Ahmad Rosdi,I Ahmed,S Ahmed,J Aiello,A Aitken,R AitSadi,S Aker,S Akimoto,A Akinfolarin,S Akram,F Alberici,C Albert,L Aldrich,M Alegata,L Alexander,S Alfaress,M Alhadj Ali,A Ali,R Alicic,A Aliu,R Almaraz,R Almasarwah,J Almeida,A Aloisi,L Al-Rabadi,D Alscher,P Alvarez,B Al-Zeer,M Amat,C Ambrose,H Ammar,Y An,L Andriaccio,K Ansu,A Apostolidi,N Arai,H Araki,S Araki,A Arbi,O Arechiga,S Armstrong,T Arnold,S Aronoff,W Arriaga,J Arroyo,D Arteaga,S Asahara,A Asai,N Asai,S Asano,M Asawa,MF Asmee,F Aucella,M Augustin,A Avery,A Awad,IY Awang,M Awazawa,A Axler,W Ayub,Z Azhari,R Baccaro,C Badin,B Bagwell,E Bahlmann-Kroll,AZ Bahtar,D Bains,H Bajaj,R Baker,E Baldini,B Banas,D Banerjee,S Banno,S Bansal,S Barberi,S Barnes,C Barnini,C Barot,K Barrett,R Barrios,B Bartolomei Mecatti,I Barton,J Barton,W Basily,S Bavanandan,A Baxter,L Becker
Journal
The Lancet Diabetes & Endocrinology
Published Date
2024/1/1
Prediction of the development of new coronary atherosclerotic plaques with radiomics
BackgroundRadiomics is expected to identify imaging features beyond the human eye. We investigated whether radiomics can identify coronary segments that will develop new atherosclerotic plaques on coronary computed tomography angiography (CCTA).MethodsFrom a prospective multinational registry of patients with serial CCTA studies at ≥ 2-year intervals, segments without identifiable coronary plaque at baseline were selected and radiomic features were extracted. Cox models using clinical risk factors (Model 1), radiomic features (Model 2) and both clinical risk factors and radiomic features (Model 3) were constructed to predict the development of a coronary plaque, defined as total PV ≥ 1 mm3, at follow-up CCTA in each segment.ResultsIn total, 9583 normal coronary segments were identified from 1162 patients (60.3 ± 9.2 years, 55.7% male) and divided 8:2 into training and test sets. At follow …
Authors
Sang-Eun Lee,Youngtaek Hong,Jongsoo Hong,Juyeong Jung,Ji Min Sung,Daniele Andreini,Mouaz H Al-Mallah,Matthew J Budoff,Filippo Cademartiri,Kavitha Chinnaiyan,Jung Hyun Choi,Eun Ju Chun,Edoardo Conte,Ilan Gottlieb,Martin Hadamitzky,Yong Jin Kim,Byoung Kwon Lee,Jonathon A Leipsic,Erica Maffei,Hugo Marques,Pedro de Araújo Gonçalves,Gianluca Pontone,Sanghoon Shin,Peter H Stone,Habib Samady,Renu Virmani,Jagat Narula,Leslee J Shaw,Jeroen J Bax,Fay Y Lin,James K Min,Hyuk-Jae Chang
Journal
Journal of Cardiovascular Computed Tomography
Published Date
2024/2/19
Nontraditional Risk Markers for Incident Coronary Artery Calcium Among Persons≥ 65 Years of Age
Background The initiation of coronary artery calcium (CAC) is an important physiologic milestone associated with increased cardiovascular disease risk. However, traditional risk factors (RF) do not perform well for predicting incident CAC among the 54 million older U.S. adults. Objectives The authors sought to assess the association between nontraditional cardiovascular disease RF and incident CAC in older persons. Methods There were 815 MESA (Multi-Ethnic Study of Atherosclerosis) participants ≥65 years of age who had CAC = 0 at Visit 1 and a follow-up CAC scan. Multivariable adjusted Cox hazards ratios (aHR) and C-statistics were calculated to examine the association of nontraditional RF with incident CAC. Results The mean age was 70.2 years and 67% were women. The median follow-up time to repeat CAC scan was 3.6 years (IQR: 2.6-9.2 years) and 45% of participants developed incident CAC …
Authors
Alexander C Razavi,Omar Dzaye,Erin D Michos,Matthew J Budoff,Norrina B Allen,Joao AC Lima,Joseph F Polak,Wendy S Post,Khurram Nasir,Roger S Blumenthal,Laurence S Sperling,Michael J Blaha,Seamus P Whelton
Journal
JACC: Advances
Published Date
2024/2/1
Professor FAQs
What is Matthew J. Budoff MD's h-index at University of California, Los Angeles?
The h-index of Matthew J. Budoff MD has been 111 since 2020 and 159 in total.
What are Matthew J. Budoff MD's top articles?
The articles with the titles of
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial
Closing the Last Mile Gap in Access to Multimodality Imaging in Rural Settings: Design of the Imaging Core of the Risk Underlying Rural Areas Longitudinal Study
Social disadvantage, coronary artery calcium, and their interplay in the prediction of atherosclerotic cardiovascular disease events
The Impact of Semaglutide on Liver Fat Assessed by Serial Cardiac CT scans in Patients with Type 2 Diabetes: Results from STOP Trial
Coronary artery calcium score predicts major adverse cardiovascular events in stable chest pain
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Prediction of the development of new coronary atherosclerotic plaques with radiomics
Nontraditional Risk Markers for Incident Coronary Artery Calcium Among Persons≥ 65 Years of Age
...
are the top articles of Matthew J. Budoff MD at University of California, Los Angeles.
What are Matthew J. Budoff MD's research interests?
The research interests of Matthew J. Budoff MD are: Cardiology, Atherosclerosis, Cardiac Imaging
What is Matthew J. Budoff MD's total number of citations?
Matthew J. Budoff MD has 189,834 citations in total.